Article ; Online: Surgical management of rectal cancer with synchronous treatment of prostate cancer.
Langenbeck's archives of surgery
2024 Volume 409, Issue 1, Page(s) 133
Abstract: Purpose: To assess the safety and efficacy of synchronous treatments for rectal (RC) and prostate (PC) cancers.: Methods: Single-center retrospective study (2007-2021) of patients treated with neoadjuvant radiotherapy (RT) and total mesorectal ... ...
Abstract | Purpose: To assess the safety and efficacy of synchronous treatments for rectal (RC) and prostate (PC) cancers. Methods: Single-center retrospective study (2007-2021) of patients treated with neoadjuvant radiotherapy (RT) and total mesorectal excision (TME) for RC with synchronous PC treatment. The endpoints were 30-day postoperative severe complications, R0 resection rates, 3-year disease-free survival (DFS) and 3-year overall survival (OS). Results: Among the 16 patients, 15 (93.7%) received neoadjuvant pelvic RT (40-50.4 Gray) followed by either transperineal high dose rate prostate brachytherapy (62.5%), prostate external RT boost (25.0%), or androgen deprivation therapy (ADT) alone (6.3%). One (6.3%) patient received neoadjuvant rectal brachytherapy and ADT. Pelvic RT was combined with chemotherapy in 87.5% of cases. TME was performed in all patients with low anterior resection (87.5%) or abdominoperineal resection (12.5%), primarily using minimally invasive surgery (87.5%). The R0 resection rate was 93.8%. Six (37.5%) patients experienced 30-day Clavien-Dindo grade IIIb complications, including one (7.1%) anastomotic leak. After a median follow-up of 39.0 months, 63.6% of diverting ileostomies were reversed. Three-year DFS from RC was 71.4% (CI 40.2-88.3) and 3-year OS was 84.4% (CI 95% 50.4-95.9). No PC recurrence or death occurred. Conclusions: Synchronous management of RC and PC with pelvic RT followed by curative prostate RT doses and TME showed acceptable morbidity and oncologic results. Prostate brachytherapy, the most commonly used treatment modality, allowed avoidance of prostatectomy and additional external RT to the rectum. PC should not limit the curative intent of RC, as all recurrences were from rectal origin. |
---|---|
MeSH term(s) | Male ; Humans ; Prostatic Neoplasms/radiotherapy ; Prostatic Neoplasms/surgery ; Androgen Antagonists/therapeutic use ; Retrospective Studies ; Follow-Up Studies ; Rectal Neoplasms/surgery ; Rectal Neoplasms/radiotherapy ; Neoadjuvant Therapy ; Treatment Outcome |
Chemical Substances | Androgen Antagonists |
Language | English |
Publishing date | 2024-04-20 |
Publishing country | Germany |
Document type | Journal Article |
ZDB-ID | 1423681-3 |
ISSN | 1435-2451 ; 1435-2443 |
ISSN (online) | 1435-2451 |
ISSN | 1435-2443 |
DOI | 10.1007/s00423-024-03327-7 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Uk I Zs.10: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.